Sci-Engi-Medco Solutions is Drug Discovery in United States that focus on responsive resistant cells business. Founded in 2011. They cover business area such as operator, cancer drug, technology, Apoptosis Pathway, both cancer stem cell, low-responsive resistant cell, doctor, chemotherapy work, combine tumor regression, cardiotoxicity.
2011
( 15 years old in 2026 )
Responsive Resistant Cells
-
573 Lexington Landing Pl
Saint Charles, MO 63303-1750
United States
Private
operatorcancer drugtechnologyApoptosis Pathwayboth cancer stem celllow-responsive resistant celldoctorchemotherapy workcombine tumor regressioncardiotoxicity
* We use standard office opening hours in near Sci-Engi-Medco Solutions's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Sci-Engi-Medco Solutions is Drug Discovery business from United States that founded in 2011 (15 years old in 2026), Sci-Engi-Medco Solutions business is focusing on Responsive Resistant Cells.
Sci-Engi-Medco Solutions headquarter office and corporate office address is located in 573 Lexington Landing Pl Saint Charles, MO 63303-1750 United States.
Sci-Engi-Medco Solutions was founded in United States.
In 2026, Sci-Engi-Medco Solutions is currently focus on responsive resistant cells sector.
Above is snippet of Google Trends for "responsive resistant cells" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Sci-Engi-Medco Solutions, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
